Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Other Pulmonary Disorders

Other Pulmonary Disorders

Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...

Pulmonary Tuberculosis II

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

Cystic Fibrosis: Pathogenesis

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The ARDS, Pneumonia, and Sepsis (APS) Consortium: Rationale, Design, and Feasibility of a National Platform for Phenotyping Critical Illness Syndromes.

Chest·2026

Same author

Diagnostic criteria for invasive pulmonary aspergillosis in COPD patients.

American journal of respiratory and critical care medicine·2026

Same author

The Disproportionate Burden of Cardiovascular Disease in Mild-to-Moderate COPD.

International journal of chronic obstructive pulmonary disease·2026

Same author

Cerebrospinal fluid transcriptional immune pathways linked to survival in HIV-associated tuberculous meningitis.

The Journal of infectious diseases·2026

Same author

Endocarditis Due to <i>Scedosporium</i> spp and <i>Lomentospora prolificans</i>: Case Series and Literature Review.

Open forum infectious diseases·2026

Same author

Mucoactive therapies and the European Respiratory Society guideline for adult bronchiectasis: what now after the CLEAR trial?

The European respiratory journal·2026

Search research articles

Related Experiment Video

Updated: Jun 11, 2025

Efficient Method for Imaging Murine Lungs that Preserves Spatial Dynamics of Fungal Spores in the Airways

Efficient Method for Imaging Murine Lungs that Preserves Spatial Dynamics of Fungal Spores in the Airways

Published on: December 13, 2024

Fungal lung disease.

Tavleen Kaur Jaggi¹, Ritesh Agarwal², Pei Yee Tiew^1,3,4

¹Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.

The European Respiratory Journal

|October 3, 2024

Summary

Fungal lung diseases, especially those caused by Aspergillus, pose a global health challenge. Advances in diagnosis and treatment are emerging, but drug resistance and diagnostic accuracy remain key concerns.

More Related Videos

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Published on: March 9, 2018

Confocal Laser Scanning Microscopy-Based Quantitative Analysis of Aspergillus fumigatus Conidia Distribution in Whole-Mount Optically Cleared Mouse Lung

Confocal Laser Scanning Microscopy-Based Quantitative Analysis of Aspergillus fumigatus Conidia Distribution in Whole-Mount Optically Cleared Mouse Lung

Published on: September 18, 2021

Related Experiment Videos

Last Updated: Jun 11, 2025

Efficient Method for Imaging Murine Lungs that Preserves Spatial Dynamics of Fungal Spores in the Airways

Efficient Method for Imaging Murine Lungs that Preserves Spatial Dynamics of Fungal Spores in the Airways

Published on: December 13, 2024

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Published on: March 9, 2018

Confocal Laser Scanning Microscopy-Based Quantitative Analysis of Aspergillus fumigatus Conidia Distribution in Whole-Mount Optically Cleared Mouse Lung

Confocal Laser Scanning Microscopy-Based Quantitative Analysis of Aspergillus fumigatus Conidia Distribution in Whole-Mount Optically Cleared Mouse Lung

Published on: September 18, 2021

Area of Science:

Pulmonology
Mycology
Infectious Diseases

Background:

Fungal lung diseases represent a significant global health burden.
Disease presentation varies based on host immunity and fungal strain, with Aspergillus species being most common.
Epidemiology is influenced by geography, environment, and host comorbidities.

Purpose of the Study:

To review the current landscape of fungal lung disease.
To highlight key clinical insights, diagnostic challenges, and emerging treatment approaches.
To discuss the impact of drug resistance and potential future strategies.

Main Methods:

This is a state-of-the-art review.
It synthesizes current knowledge on fungal lung disease diagnosis and treatment.
It examines evolving diagnostic modalities and therapeutic strategies.

Main Results:

Diagnosis remains challenging, particularly in resource-limited settings, with difficulties in rapid and accurate identification.
Antifungal drug resistance is a growing global threat, complicating treatment.
Emerging antifungal agents and understanding the lung mycobiome offer potential for personalized medicine.

Conclusions:

Accurate and timely diagnosis of fungal lung diseases is critical.
Combating antifungal drug resistance requires innovative methodologies.
Future approaches may involve personalized medicine informed by the lung mycobiome.